glp-1 shortage update Pipeline Update: August 2025 - Prime Therapeutics What's next for GLP-1 innovation:

NAFLD: pathophysiological aspects Long before individuals with IR experience defects of glucose metabolism, increased circulating levels of non-esterified fatty acids (NEFAs) are found

Early data suggests that while retatrutide produces more dramatic weight loss, the gastrointestinal side effect patterns may differ from those seen with semaglutide alone

The culmination of these scientific advancements provides valuable insights for the development of more effective treatments for metabolic disorders, ultimately paving the way for improved patient outcomes in the realm of metabolic health

Drug coverage works through layers of approval

Results Here we show that gene expression of GLP-1R in pancreas is associated with a reduced risk of overall ovarian cancer risk odds ratio ([OR] = 0.94, 95% confidence interval [CI] 0.89-1.00) and endometrioid ovarian cancer (ENOC

About this article Cite this article Hammoud, R., Drucker, D.J